[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06723015":3,"trial-entities:NCT06723015":81,"trial-summary:NCT06723015":88},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":22,"study_type":23,"primary_purpose":14,"phases":24,"enrollment_info":26,"interventions":29,"primary_outcomes":36,"secondary_outcomes":41,"sex":46,"minimum_age":47,"maximum_age":48,"healthy_volunteers":15,"eligibility_criteria":49,"std_ages":62,"locations":65,"central_contacts":74,"overall_officials":75,"references":79,"see_also_links":80},"NCT06723015","24-004371","Tau PET Outcomes With Anti-amyloid Immunotherapies","Study of Tau PET Outcomes in Patients Receiving Anti-amyloid Immunotherapies","ENROLLING_BY_INVITATION","2028-08","2025-11","2025-11-18","2025-11-04","Mayo Clinic","OTHER",false,"This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.",null,[19,20,21],"Cognitive Impairment, Mild","Dementia, Mild","Alzheimer Disease",[],"INTERVENTIONAL",[25],"PHASE2",{"count":27,"type":28},135,"ESTIMATED",[30],{"type":31,"name":32,"description":33,"armGroupLabels":34},"DRUG","18F-AV-1451","Subjects will receive two Tau PET (18F--AV-1451) brain scans with approximately 10 mCi (370 MBq) (+\u002F- 10%mCi) of 18F-AV-1451. Images will be collected for a 20-minute acquisition between 80-100 minutes after injection.\n\nTau PET scans will occur at baseline and 12-18 months after completing anti-amyloid immunotherapy treatment..",[35],"Treatment Group",[37],{"measure":38,"description":39,"timeFrame":40},"Change in tau PET Standardized Uptake Value (SUVR)","A PET Standardized Uptake Value (SUV) is measured by calculating the ratio of the radioactivity concentration within a specific region of interest (ROI) on a PET scan, divided by the injected dose of the radiotracer per unit of the patient's body weight. The calculated Standardized Uptake Value (SUVR) is reported as a single number, with higher values indicating greater tracer uptake in the target region relative to the reference region","Baseline, 18 months",[42],{"measure":43,"description":44,"timeFrame":45},"Number of subjects to develop amyloid-related imaging abnormalities (ARIA)","ARIA is defined as edema (parenchymal edema or sulcal effusion, ARIA-E) and hemorrhage (microhemorrhages and superficial siderosis, ARIA-H). ARIA is detected on the patient's routine clinical brain MRIs.","18 months","ALL","50 Years","90 Years",{"inclusion":50,"exclusion":57,"raw_text":61},[51,52,53,54,55,56],"Age 50-90 years","Male or female","Mild cognitive impairment due to AD or mild AD","Amyloid positive via CSF or PET","Meets other eligibility criteria for anti-amyloid immunotherapy","Subject or delegate provides informed consent",[58,59,60],"Subjects unable to lie down without moving for 10 minutes.","Women who are pregnant or cannot stop breast feeding for 24 hours.","Claustrophobic patients unable to tolerate the scans (no sedation can be offered).","Inclusion Criteria\n\n* Age 50-90 years\n* Male or female\n* Mild cognitive impairment due to AD or mild AD\n* Amyloid positive via CSF or PET\n* Meets other eligibility criteria for anti-amyloid immunotherapy\n* Subject or delegate provides informed consent\n\nExclusion Criteria\n\n* Subjects unable to lie down without moving for 10 minutes.\n* Women who are pregnant or cannot stop breast feeding for 24 hours.\n* Claustrophobic patients unable to tolerate the scans (no sedation can be offered).",[63,64],"ADULT","OLDER_ADULT",[66],{"facility":13,"city":67,"state":68,"zip":69,"country":70,"geoPoint":71},"Rochester","Minnesota","55905","United States",{"lat":72,"lon":73},44.02163,-92.4699,[],[76],{"name":77,"affiliation":13,"role":78},"Petrice Cogswell, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":82,"biomarkers":86},[83,84,85],"Alzheimer's Disease","Mild cognitive disorder","Mild dementia",[87],"Amyloid",{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]